Literature DB >> 23362524

Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis.

M Carrier1, A A Khorana, J I Zwicker, G H Lyman, G Le Gal, A Y Y Lee.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23362524     DOI： 10.1111/jth.12028

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  5 in total

Review 1.  Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis.

Authors:  Minh Phan; Sonia John; Ana I Casanegra; Suman Rathbun; Aaron Mansfield; Julie A Stoner; Alfonso J Tafur
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

2.  Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia.

Authors:  H Sibai; J T Seki; T Q Wang; N Sakurai; E G Atenafu; K W L Yee; A C Schuh; V Gupta; M D Minden; A D Schimmer; J M Brandwein
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

3.  Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials.

Authors:  A S Mansfield; A J Tafur; D Vulih; G L Smith; P J Harris; S P Ivy
Journal:  Thromb Res       Date:  2015-10-20       Impact factor: 3.944

4.  Estimating incidence of venous thromboembolism in COVID-19: Methodological considerations.

Authors:  Linda Nab; Rolf H H Groenwold; Frederikus A Klok; Soerajja Bhoelan; Marieke J H A Kruip; Suzanne C Cannegieter
Journal:  Res Pract Thromb Haemost       Date:  2022-08-15

Review 5.  Cancer Therapy-Associated Thrombosis.

Authors:  Steven P Grover; Yohei M Hisada; Raj S Kasthuri; Brandi N Reeves; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-11       Impact factor: 8.311
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.